Hua Yuan Zheng Quan·2026-03-02 05:25Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical market showed a modest increase of 0.50% from February 24 to February 27, with a relative underperformance of -0.58% compared to the CSI 300 index. The focus is on companies with strong Q1 performance and undervalued innovative drug stocks, particularly those with price increase expectations [5] - The report highlights the upcoming commercialization of Eli Lilly's oral weight loss drug, Orforglipron, which is expected to lead the global market for small molecule GLP-1 receptor agonists [3][19] - The report emphasizes the transformation of the Chinese pharmaceutical industry, which has completed a transition from generics to innovation, with companies like Heng Rui Medicine and Hansoh Pharmaceutical making significant strides in global markets [5][46] Summary by Sections 1. Orforglipron - Orforglipron, developed by Eli Lilly, has shown superior efficacy in reducing HbA1c and body weight compared to oral Semaglutide in the ACHIEVE-3 study, with a 52-week HbA1c reduction of 2.2% versus 1.4% for Semaglutide [10][19] - The drug is expected to receive approval for obesity indications in the US by Q2 2026, with diabetes indications to follow later in the year [19][20] - Domestic companies are rapidly advancing in the oral GLP-1RA space, with several in late-stage clinical trials and some already securing international licensing agreements [21] 2. Industry Perspective - The report suggests a dual investment framework focusing on "technology innovation" and "performance/valuation recovery" for the year [25] - The pharmaceutical index has shown a year-to-date increase of 2.96%, with a notable number of stocks experiencing significant gains [25] - The aging population and chronic disease prevalence are driving demand, while the healthcare payment system is evolving to support multi-layered insurance structures [46]